Funds › Catalio Capital Management, LP
Catalio Capital Management, LP
13F for Q2 2026, filed Aug 14, 2026. 39 positions worth $532.1M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q2 2026
filed Aug 14, 2026
Reported value
$532.1M
+$53.4M (11.2%) vs Q1 2026
Positions
39
41 in Q1 2026
Top 10 share
56.7%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Catalio Capital Management, LP in the latest 13F quarter?
Using 13F.ai, how has Catalio Capital Management, LP's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Catalio Capital Management, LP's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | AVLN Avalyn Pharma Inc. | 1.68M | $55.2M | 10.4% | New | 13F ↗ |
| 2 | JNJ Johnson & Johnson | 138,946 | $35.3M | 6.6% | New | 13F ↗ |
| 3 | GILD Gilead Sciences, Inc. | 269,309 | $34.0M | 6.4% | +64.3% | 13F ↗ |
| 4 | BBIO BridgeBio Pharma, Inc. | 455,041 | $33.9M | 6.4% | +5.3% | 13F ↗ |
| 5 | SNDX Syndax Pharmaceuticals, Inc. | 1.22M | $26.6M | 5.0% | +16.5% | 13F ↗ |
| 6 | DFTX Definium Therapeutics, Inc. | 562,672 | $26.5M | 5.0% | -45.8% | 13F ↗ |
| 7 | BMY Bristol-Myers Squibb Company | 412,961 | $23.8M | 4.5% | -1.8% | 13F ↗ |
| 8 | PBLS Parabilis Medicines, Inc. | 824,043 | $22.6M | 4.2% | New | 13F ↗ |
| 9 | NTRA Natera, Inc. | 82,181 | $22.3M | 4.2% | +15.9% | 13F ↗ |
| 10 | INCY Incyte Corporation | 191,627 | $21.7M | 4.1% | +5.2% | 13F ↗ |
| 11 | SEPN Septerna, Inc. | 536,152 | $18.0M | 3.4% | +82.1% | 13F ↗ |
| 12 | MLYS Mineralys Therapeutics, Inc. | 648,722 | $17.5M | 3.3% | +47.8% | 13F ↗ |
| 13 | HTFL Heartflow, Inc. | 583,055 | $17.1M | 3.2% | +44.5% | 13F ↗ |
| 14 | CRVS Corvus Pharmaceuticals, Inc. | 1.08M | $16.1M | 3.0% | +21.2% | 13F ↗ |
| 15 | GPCR Structure Therapeutics Inc. | 276,550 | $14.8M | 2.8% | +8.3% | 13F ↗ |
| 16 | PTGX Protagonist Therapeutics, Inc. | 106,799 | $13.1M | 2.5% | New | 13F ↗ |
| 17 | IRON Disc Medicine, Inc. | 159,384 | $11.7M | 2.2% | +29.6% | 13F ↗ |
| 18 | EW Edwards Lifesciences Corporation | 124,778 | $11.3M | 2.1% | -13.7% | 13F ↗ |
| 19 | AXSM Axsome Therapeutics, Inc. | 43,182 | $10.6M | 2.0% | New | 13F ↗ |
| 20 | RARE Ultragenyx Pharmaceutical Inc. | 316,252 | $10.6M | 2.0% | -62.8% | 13F ↗ |
| 21 | KLRA Kailera Therapeutics, Inc. | 468,750 | $10.3M | 1.9% | New | 13F ↗ |
| 22 | KPTI Karyopharm Therapeutics Inc. | 940,855 | $9.2M | 1.7% | +4.8% | 13F ↗ |
| 23 | ODTX Odyssey Therapeutics, Inc. | 457,839 | $8.6M | 1.6% | New | 13F ↗ |
| 24 | ASND Ascendis Pharma A/S | 31,759 | $8.5M | 1.6% | New | 13F ↗ |
| 25 | KARD Kardigan, Inc. | 312,500 | $7.5M | 1.4% | New | 13F ↗ |
| 26 | ELDN Eledon Pharmaceuticals, Inc. | 1.70M | $6.7M | 1.3% | +3.4% | 13F ↗ |
| 27 | FDMT 4D Molecular Therapeutics, Inc. | 471,254 | $6.3M | 1.2% | New | 13F ↗ |
| 28 | MANE Veradermics, Incorporated | 45,856 | $5.6M | 1.1% | -73.6% | 13F ↗ |
| 29 | DYN Dyne Therapeutics, Inc. | 244,929 | $5.4M | 1.0% | -13.4% | 13F ↗ |
| 30 | Fractyl Health Inc | 6.17M | $4.9M | 0.9% | +12.3% | 13F ↗ |
| 31 | IMCR Immunocore Holdings plc · ADR | 148,045 | $4.7M | 0.9% | +75.5% | 13F ↗ |
| 32 | DNTH Dianthus Therapeutics, Inc. | 32,941 | $3.2M | 0.6% | -94.1% | 13F ↗ |
| 33 | BBOT BridgeBio Oncology Therapeutics, Inc. | 318,407 | $2.4M | 0.5% | New | 13F ↗ |
| 34 | TARA Protara Therapeutics, Inc. | 520,148 | $2.0M | 0.4% | -10.3% | 13F ↗ |
| 35 | HYPR Hyperfine, Inc. | 1.32M | $1.8M | 0.3% | Unchanged | 13F ↗ |
| 36 | Ataibeckley Inc | 196,858 | $1.0M | 0.2% | Unchanged | 13F ↗ |
| 37 | MGX Metagenomi Therapeutics, Inc. | 528,993 | $629.5K | 0.1% | Unchanged | 13F ↗ |
| 38 | OM Outset Medical, Inc. | 118,279 | $511.0K | 0.1% | Unchanged | 13F ↗ |
| 39 | FTH Faeth Therapeutics, Inc. | 14,718 | $367.9K | 0.1% | Unchanged | 13F ↗ |
Changes since Q1 2026
11 new, 15 added to, 8 trimmed, 13 exited, 5 unchanged. By estimated dollars.
New positions (11)
| AVLN Avalyn Pharma Inc. | 1.68M | New | $55.2M |
| JNJ Johnson & Johnson | 138,946 | New | $35.3M |
| PBLS Parabilis Medicines, Inc. | 824,043 | New | $22.6M |
| PTGX Protagonist Therapeutics, Inc. | 106,799 | New | $13.1M |
| AXSM Axsome Therapeutics, Inc. | 43,182 | New | $10.6M |
| KLRA Kailera Therapeutics, Inc. | 468,750 | New | $10.3M |
| ODTX Odyssey Therapeutics, Inc. | 457,839 | New | $8.6M |
| ASND Ascendis Pharma A/S | 31,759 | New | $8.5M |
| KARD Kardigan, Inc. | 312,500 | New | $7.5M |
| FDMT 4D Molecular Therapeutics, Inc. | 471,254 | New | $6.3M |
Added to (15)
| GILD Gilead Sciences, Inc. | 269,309 | +64.3% | $13.3M |
| SEPN Septerna, Inc. | 536,152 | +82.1% | $8.1M |
| MLYS Mineralys Therapeutics, Inc. | 648,722 | +47.8% | $5.7M |
| HTFL Heartflow, Inc. | 583,055 | +44.5% | $5.3M |
| SNDX Syndax Pharmaceuticals, Inc. | 1.22M | +16.5% | $3.8M |
| NTRA Natera, Inc. | 82,181 | +15.9% | $3.1M |
| CRVS Corvus Pharmaceuticals, Inc. | 1.08M | +21.2% | $2.8M |
| IRON Disc Medicine, Inc. | 159,384 | +29.6% | $2.7M |
| IMCR Immunocore Holdings plc · ADR | 148,045 | +75.5% | $2.0M |
| BBIO BridgeBio Pharma, Inc. | 455,041 | +5.3% | $1.7M |
Trimmed (8)
| DNTH Dianthus Therapeutics, Inc. | 32,941 | -94.1% | -$51.4M |
| DFTX Definium Therapeutics, Inc. | 562,672 | -45.8% | -$22.4M |
| RARE Ultragenyx Pharmaceutical Inc. | 316,252 | -62.8% | -$17.8M |
| MANE Veradermics, Incorporated | 45,856 | -73.6% | -$15.7M |
| EW Edwards Lifesciences Corporation | 124,778 | -13.7% | -$1.8M |
| DYN Dyne Therapeutics, Inc. | 244,929 | -13.4% | -$844.5K |
| BMY Bristol-Myers Squibb Company | 412,961 | -1.8% | -$447.5K |
| TARA Protara Therapeutics, Inc. | 520,148 | -10.3% | -$228.7K |
Exited (13)
| Ascendis Pharma A/S ADR | 129,111 | Exited | -$29.5M |
| Terns Pharmaceuticals Inc | 409,031 | Exited | -$21.6M |
| Soleno Therapeutics Inc | 577,808 | Exited | -$19.3M |
| BSX Boston Scientific Corporation | 299,318 | Exited | -$18.8M |
| CYTK Cytokinetics, Incorporated | 215,501 | Exited | -$14.2M |
| ADPT Adaptive Biotechnologies Corporation | 722,784 | Exited | -$10.0M |
| Kalvista Pharmaceuticals Inc | 426,551 | Exited | -$8.6M |
| QURE uniQure N.V. | 491,116 | Exited | -$8.0M |
| ABVX Abivax SA · ADR | 47,193 | Exited | -$5.3M |
| SUPN Supernus Pharmaceuticals | 62,019 | Exited | -$3.2M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer